2018-2023 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Report

  • No of Pages: 145
  • Publisher: LP Information
  • Category: Others
20off

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Benign Prostatic Hyperplasia (BPH) Drugs market for 2018-2023.

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
Over the next five years, LPI(LP Information) projects that Benign Prostatic Hyperplasia (BPH) Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
Segmentation by application:
Men
Women

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments.
Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Benign Prostatic Hyperplasia (BPH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

3 Reports

USD 8,250
  • PDF
  • EXCEL DATA (NO)
  • PPT (NO)
  • HARD COPY (NO)
  • 15% FREE CUSTOMISATION
  • 5 USERS
  • 3 ANALYST CALL
  • Add to cart

6 Reports

USD 15,000
  • PDF
  • EXCEL DATA
  • PPT (NO)
  • HARD COPY (NO)
  • 20% FREE CUSTOMISATION
  • 10 USERS
  • 12 ANALYST CALL
  • Add to cart

9 Reports

USD 20,250
  • PDF
  • EXCEL DATA
  • PPT
  • HARD COPY (NO)
  • 25% FREE CUSTOMISATION
  • 20 USERS
  • 22 ANALYST CALL
  • Add to cart

12 Reports

USD 24,000
  • PDF
  • EXCEL DATA
  • PPT
  • HARD COPY (NO)
  • 30% FREE CUSTOMISATION
  • UNLIMITED
  • 36 ANALYST CALL
  • Add to cart

Table of Contents

2018-2023 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2023
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
2.2.1 Alpha-Blocker
2.2.2 Phosphodiesterase Type-5 Inhibitors
2.2.3 5-Alpha-Reductase Inhibitors
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2013-2018)
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
2.4.1 Men
2.4.2 Women
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value and Market Share by Application (2013-2018)
2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2013-2018)

3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Players
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2016-2018)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players (2016-2018)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Players (2016-2018)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players (2016-2018)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
4.1 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions
4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth

5 Americas
5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
10.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer

11 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast
11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2018-2023)
11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
11.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions (2018-2023)
11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type
11.8 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application

12 Key Players Analysis
12.1 Astellas Pharma
12.1.1 Company Details
12.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Astellas Pharma News
12.2 Eli Lilly
12.2.1 Company Details
12.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Eli Lilly News
12.3 GlaxoSmithKline
12.3.1 Company Details
12.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 GlaxoSmithKline News
12.4 Sanofi
12.4.1 Company Details
12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Sanofi News
12.5 ADC Therapeutics
12.5.1 Company Details
12.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 ADC Therapeutics News
12.6 Bayer HealthCare
12.6.1 Company Details
12.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Bayer HealthCare News
12.7 Bristol-Myers Squibb
12.7.1 Company Details
12.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Bristol-Myers Squibb News
12.8 Valeant Pharmaceuticals
12.8.1 Company Details
12.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Valeant Pharmaceuticals News
12.9 Endo Pharmaceuticals
12.9.1 Company Details
12.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.9.4 Main Business Overview
12.9.5 Endo Pharmaceuticals News
12.10 Foresee Pharmaceuticals
12.10.1 Company Details
12.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
12.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
12.10.4 Main Business Overview
12.10.5 Foresee Pharmaceuticals News

13 Research Findings and Conclusion

Research Process

The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistic agencies, and paid databases. This information creates a base for the study. This information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analysed to extract crisp data points which currently affect or are likely to affect the industry over the forecast period. After analysing the information, a proprietary market estimation & forecast technique is applied, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for over the forecast period. After populating the market sizes & estimates, numbers are verified with the industry participants and key opinion leaders. The wide network of industry participants performs a value addition in the research and verify the numbers & estimates of the study. In the last stage of the research process, a final report is prepared which is then published on different websites as well as distributed through various channels. Below figure contains the different stages of the whole research performed to produce the report.

After populating the market sizes & estimates, numbers are verified with the industry participants and key opinion leaders. The wide network of industry participants performs a value addition in the research and verify the numbers & estimates of the study. In the last stage of the research process, a final report is prepared which is then published on different websites as well as distributed through various channels. Below figure contains the different stages of the whole research performed to produce the report.

DATA MINING

Data mining is one of the extensive stages of our research process. It involves the procurement of market data and related information through different verified & credible sources. This step helps to obtain the raw information about the supply chain of the industry, the monetary process of different Products & End-Uses, the pool of market participants & the nature of the industry and the scope of the study. The data mining stage comprises both primary as well as secondary sources of information. Some of the key data sources are as follows:

Secondary Research In the process of secondary research, various sources are referred to identify and collect industry trends and information for the research process. We at having access to some of the most diversified and extensive paid databases which give us the most accurate data/information on markets sizes, Products and pricing.

In the primary research process for data mining, various key industry participants from both supply and demand side are interviewed to obtain both qualitative as well as quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (SMEs), industry consultants, and C-level executives of major companies are conducted to obtain critical qualitative and quantitative aspects pertaining to the market, as well as to assess the prospects for market growth over the forecast period.

ANALYSIS

This step involves the analysis & mapping of all the information procured from the previous step. This step also encompasses the scrutiny of data discrepancies observed across various data sources and finalising the appropriate data for estimation and forecasting. This analysis is done by our experienced panel of industry analysts.

MARKET ESTIMATION

Understanding and penetrating the market in terms of valuation is a crucial task in the process of business research. This again becomes significantly important while investing and choosing the business opportunities. In this regard, we perform two ways market sizing approach simultaneously namely top-down and bottom-up approaches. In this step, we place different data points, numeric attributes, information, and industry trends at an appropriate space in order to deduce the estimates & forecast values over the coming years. We use different mathematical models to estimate the market sizes of different economies and segments. Each of which is further summed up to define the total market. We own a proprietary tool for market estimations which helps us to comprehend market size estimates & forecasts for different markets and industries. Below figure explains the process of market estimation using independent tool employed by our analysts to get the sizing off the market.